Studien
Pages
Projekte
- ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- Clinicopathological characteristics of RET rearranged lung cancer in European patients
- MET - ein vielversprechendes Target
- Developments in oncological positron emission tomography/computed tomography assessment
- Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases
- Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
- NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
- Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.
- Comprehensive genomic profiles of small cell lung cancer.
- Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
- Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
- ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
- Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.
- PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
- PD-L1 expression in small cell neuroendocrine carcinomas.
- Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.
- MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
- ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer
- PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.
- Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
- Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib
- CD74-NRG1 Fusions in Lung Adenocarcinoma
- Ceritinib in ALK-rearranged non-small-cell lung cancer
- Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
- Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer
- A Genomics-Based Classification of Human Lung Tumors
- Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer
- Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib
- Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
- FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications
- Activated RET and ROS: two new driver mutations in lung adenocarcinoma
- Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
- Molecular pathology of the lungs. New perspectives by next generation sequencing
- Lung Cancer: Molecular pathology and personalized therapy
- Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib
- Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
- Genetic insight and therapeutic targets in squamous-cell lung cancer
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- A framework for identification of actionable cancer genome dependencies in small cell lung cancer
- Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET
- Indications and limitations of fresh frozen sections in the pulmonary apparatus
- Comprehensive genomic characterization of squamous cell lung cancers
- Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
- Early palliative care for patients with metastatic cancer
- Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
- Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib
- Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities
- Recommending early integration of palliative care – does it work?
- Personalized therapy of lung cancer
- The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
- Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
- A crucial requirement for Hedgehog signaling in small cell lung cancer
- Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles
- Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
- Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
- Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines
- Blood-based gene expression signatures for early detection of lung cancer
- Benchmarking of mutation diagnostics in clinical lung cancer specimens
- Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
- Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)
- Molecular diagnostics of lung cancer for treatment stratification
- Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer
- Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer
- Cytohesins Are Cytoplasmic ErbB Receptor Activators
- Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium
- Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project
- Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor
- Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors
- Identification of lung cancer with high sensitivity and specificity by blood testing
- Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation
- Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
Posts by category
- Category: Ärzte
- Friends for Ukraine
- „Dass informierte Patienten länger leben, ist bei Lungenkrebs keine Phrase.“
- Neuer Standort Nationales Centrum für Tumorerkrankungen
- Zulassungsstudie identifiziert prädikativen Biomarker METex14
- Vision Zero: Kampagne gegen Tabakwerbung
- Studie für Patienten mit EGFR-positivem Lungenkarzinom nach Osimertinib
- Angehörige überreichen Spende an Forschungsgruppe von Prof. Dr. Thomas
- 2019 World Conference on Lung Cancer
- Impressions from the 2nd Cologne Conference on Lung Cancer 2019
- Countdown is running: only a few days left until the start of CCLC 2019!
- American Society of Clinical Oncology (ASCO)
- Prof. Büttner’s statement on the upcoming CCLC 2019
- Prof. Wolf’s statement on the upcoming CCLC 2019
- European Lung Cancer Congress (ELCC) 2019
- Register Now: 2nd Cologne Conference on Lung Cancer
- Gesundheitsdaten in Patientenhand: DataBox-Projekt
- Jahrestreffen der ROS1-Patienten
- ICPerMed Conference 2018 ‘Personalised Medicine in Action’
- Das nNGM hat eine neue Webseite!
- NEUE Studie: Eine multizentrische, offene Phase-I Dosiseskalations-Studie mit EGF816 und Trametinib bei Patienten mit nicht-kleinzelligem Bronchialkarzinom und EGFR p.T790M vermittelter Resistenz auf EGFR Inhibitoren der 1. und 2. Generation
- Projektstart für das Nationale Netzwerk Genomische Medizin (nNGM) ab dem 01.04.2018
- MET Inhibition jetzt auch in der Erstlinie möglich
- G-BA Beschluss Tagrisso
- ALK-Inhibitor Resistenzdiagnostik
- Category: Innovation
- Category: Patienten
- Category: Studien
- Category: Veranstaltungen